Table 2.
Univariate analysis for OS and LRPFS
| Factor | No. of patients | 2-yr OS (%) | p-value | 2-yr LRPFS (%) | p-value |
|---|---|---|---|---|---|
| Gender | 0.800 | 0.800 | |||
| Male | 56 | 46.1 | 23.0 | ||
| Female | 10 | 58.3 | 30.0 | ||
| Age (yr) | 0.100 | 0.600 | |||
| ≤65 | 36 | 57.6 | 21.5 | ||
| >65 | 30 | 36.7 | 26.3 | ||
| Stage | 0.800 | 0.600 | |||
| IIIA | 23 | 52.2 | 22.8 | ||
| IIIB | 43 | 45.6 | 23.8 | ||
| T stage | 0.050 | 0.200 | |||
| T0–2 | 25 | 63.2 | 30.9 | ||
| T3–4 | 41 | 39.0 | 19.5 | ||
| N stage | 0.700 | 0.800 | |||
| N0–1 | 6 | 66.7 | 40.0 | ||
| N2 | 26 | 50.0 | 18.5 | ||
| N3 | 34 | 43.1 | 25.2 | ||
| Smoking history | 0.600 | 0.700 | |||
| No | 12 | 48.6 | 25.0 | ||
| Yes | 24 | 47.8 | 23.8 | ||
| ECOG performance status | 0.400 | 0.500 | |||
| 0 | 28 | 52.5 | 27.9 | ||
| 1 | 35 | 45.7 | 19.6 | ||
| 2 | 3 | 33.3 | 33.3 | ||
| Pathology | 0.700 | 0.800 | |||
| Squamous cell carcinoma | 33 | 42.4 | 24.2 | ||
| Adenocarcinoma | 29 | 52.5 | 26.9 | ||
| Others | 4 | 50.0 | - | ||
| Chemotherapy regimen | 1.000 | 0.700 | |||
| Paclitaxel/carboplatin | 37 | 48.0 | 22.5 | ||
| Docetaxel/cisplatin | 26 | 50.0 | 24.1 | ||
| Others | 3 | 33.3 | 33.3 | ||
| Radiation dose (cGy) | 0.300 | 0.800 | |||
| ≤6,600 | 63 | 47.2 | 22.9 | ||
| >6,600 | 3 | 66.7 | 50.0 | ||
| PTV volume (mL) | 0.010 | 0.100 | |||
| ≤412 | 35 | 62.6 | 31.8 | ||
| >412 | 31 | 31.1 | 16.1 | ||
| Pre-CCRT NLR | 0.090 | 0.600 | |||
| ≤1.64 | 12 | 64.8 | 36.7 | ||
| >1.64 | 54 | 44.4 | 21.5 | ||
| Pre-CCRT PLR | 0.100 | 0.700 | |||
| ≤115 | 19 | 62.7 | 28.2 | ||
| >115 | 47 | 42.5 | 22.5 | ||
| Post-CCRT NLR | <0.001 | 0.010 | |||
| ≤3.12 | 35 | 68.2 | 33.8 | ||
| >3.12 | 31 | 25.8 | 12.9 | ||
| Post-CCRT PLR | 0.004 | 0.040 | |||
| ≤141 | 21 | 71.1 | 40.3 | ||
| >141 | 45 | 37.5 | 16.5 | ||
| NLR change | <0.001 | 0.004 | |||
| ≤1.61 | 44 | 59.0 | 31.8 | ||
| >1.61 | 22 | 26.0 | 6.8 | ||
| PLR change | 0.100 | 0.200 | |||
| ≤1.67 | 48 | 49.6 | 27.0 | ||
| >1.67 | 18 | 43.8 | 16.7 | ||
| CRP (mg/dL) | 0.090 | 0.300 | |||
| ≤0.47 | 18 | 66.2 | 25.9 | ||
| >0.47 | 45 | 40.0 | 20.3 | ||
| ESR (mm/hr) | 0.200 | 0.300 | |||
| ≤15 | 9 | 66.7 | 33.3 | ||
| >15 | 54 | 44.3 | 20.3 | ||
| LDH (U/L) | 0.700 | 1.000 | |||
| ≤450 | 45 | 46.7 | 24.1 | ||
| >450 | 21 | 51.3 | 25.1 |
OS, overall survival; LRPFS, locoregional progression-free survival; ECOG, Eastern Cooperative Oncology Group; PTV, planning target volume; CCRT, concurrent chemoradiotherapy; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; NLR change, dividing the post-CCRT NLR by the pre-CCRT NLR; PLR change, dividing the post-CCRT PLR by the pre-CCRT PLR; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase.